Build or Buy? Five Questions Every Imaging Leader Should Ask Before Betting on AI
The hidden weight of building in-house AI infrastructure. What starts as control can become a burden without scale, support, and sustained investment.
Executive takeaway – Two-thirds of U.S. health-system CIOs now lean toward buying or partnering for clinical AI rather than building in-house, citing talent gaps, cost, and time-to-value. Yet radiology still commands 76 % of all FDA-cleared AI devices—proof that the specialty’s appetite (and scrutiny) remain high. Before you commit capital, run your plan through the five questions below.
1. What’s the real cost of scaling—and keeping it scaled?
Benchmark: Cloud-native imaging shops report up to 30 % lower infrastructure spend after shifting AI workloads off-prem.
Hardware costs don’t end with GPUs. You’ll bankroll 👇
|
Cost driver |
Hidden multipliers if you build |
|---|---|
|
Inference hardware |
Refresh every 18-24 months as model sizes grow |
|
Data pipelines |
PET, CT, US, and MR each need separate adapters |
|
MLOps staff |
24 × 7 monitoring, rollback, model registry |
|
Technical-debt interest |
Code rot grows exponentially unless refactored—Google calls this “hidden ML debt.” |
Ask yourself: Could we re-invest those engineering dollars closer to patient care and still get state-of-the-art AI via a partner?
2. How will we fund continuous improvement —not just a launch?
Initial AUCs fade when scanners, protocols, or patient mix change. Leaders who built early discover that 60-70% of lifecycle spend lands after go-live on:
- dataset refresh
- re-validation
- drift detection
The alternative? A vendor whose business model includes rolling upgrades and fleet-wide performance telemetry—spread across dozens of customers, not one balance sheet.
3. Can we prove robustness against AI “hallucinations”?
A 2024 analysis found 5–10% of AI-assisted radiology cases carried a misdiagnosis linked to hallucination or over-confident output.
Checklist for buyers/builders:
- Shadow-mode testing before first clinical read
- Real-time guardrails (score thresholds, abstain logic)
- Closed-loop feedback from radiologists (click-to-correct) feeding nightly retrains
If you build, each safeguard is another sprint. If you buy, verify the vendor’s validation pipeline and audit logs.
4. Will our solution stay compliant—globally?
FDA 510(k) today, EU MDR tomorrow, Health Canada and HSA next. Just as you ship v1, a new “change-control” draft guidance arrives.
- Build path: maintain a regulatory affairs team, submit new testing every time the model updates.
- Buy/partner path: off-load that paperwork; vendors amortise across their install base.
McKinsey’s 2025 survey shows 61% of healthcare organizations prefer “partnerships” for gen-AI to navigate cross-market rules, versus 20 % build-only.
5. Does it fit tomorrow’s workflow on day one?
CIO interviews reveal the #1 adoption killer: “It opens in a different window.”
Whether you buy or build, insist that AI outputs:
- Render inside your PACS/EHR viewer
- Use the same measurement units and voice-dictation macros radiologists already love
- Write to the report header without breaking transcription
Time-pressed radiologists have <15 seconds of patience for a new click.
Putting it all together
|
Decision lens |
If you build from scratch… |
Why many groups buy / partner |
|---|---|---|
|
Trusted, real-time RAG |
Stand up ≥10 retrieval + re-rank layers, monitor hallucinations 24/7, & field a red-team for prompt-injection defense. |
Ready-made safe-RAG stack with multi-layer validation and audit logs already running in production. |
|
Web-scale performance |
Design autoscaling, model-routing, and GPU optimization to handle millions of studies with sub-second latency. |
Cloud-native architecture battle-tested at consumer-internet scale; elastic shards keep cost flat as volume spikes. |
|
Zero-trust security & compliance |
Implement FIPS-grade crypto, key isolation, segmentation, annual pen-tests, and maintain HIPAA / SOC2 / MDR updates. |
Pre-certified stack with encryption-in-use, tenant vaults, continuous compliance monitoring—updates handled by vendor. |
|
Velocity of innovation |
Dual roadmaps: platform upkeep and clinical ML. Every model tweak triggers validation, FDA/MDR paperwork, and downtime windows. |
Weekly feature drops shared across the customer network; internal data-science team focuses on new clinical value, not plumbing. |
|
Lifetime cost & risk |
Ongoing OpEx for drift, hardware refresh, on-call rotations; reputational risk if a single hallucination goes public. |
Subscription with SLA shifts maintenance burden and liability; predictable spend, reversible if strategy changes. |
The bottom line
Radiology has never been more AI-ready—or more unforgiving of false starts. Leaders who answer these five questions early avoid costly detours and keep focus on what matters: faster, safer diagnoses for patients.
Ready to explore a “buy, then build on top” model?
Request a private strategy session with the Gup team.
Your complimentary 30-minute strategy session is the first step.